Details of the Drug Formulation (DFM)
| General Information of DFM (ID: F23246) | |||||
|---|---|---|---|---|---|
| Name |
Omacetaxine Mepesuccinate 3.5mg/vial powder
|
||||
| Company |
Teva Pharms Intl
|
||||
| Active Pharmaceutical Ingredient (API) | Omacetaxine mepesuccinate |
API Info
 click to show the detail info of this API
|
|||
| Approved | |||||
| Drug Inactive Ingredient (DIGs) | |||||
| DIG ID | DIG Info | DIG Name | DIG Functional Class | ||
| E0Q6DQ | DIG Info | Mannitol | Diluent ... | ||
| Full List of Biological Targets of DIG (DBTs) Regulated by DIG(s) in This DFM | ||||||
|---|---|---|---|---|---|---|
| Transmembrane channel/porin (TC/P) | ||||||
| DBT Name: Glycine receptor alpha-1 (GLRA1) | Click to Show/Hide | |||||
| Detailed Information |
DBT Info
click to show the detail info of this DBT
|
|||||
| Experiment for Assessing the Biological Activity of the Studied DIG on This DBT | ||||||
| Interacting DIG | Mannitol | |||||
| Biological Activity | EC50 = 12589.25 nM (estimated based on the structural similarity with CHEMBL604608 ) | [1] | ||||
| Structural Similarity | Tanimoto coefficient = 0.804878049 | |||||
| Tested Species | Homo sapiens (Human) | |||||
| UniProt ID | GLRA1_HUMAN | |||||
| References | |||||
|---|---|---|---|---|---|
| 1 | Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. Bioorg Med Chem Lett. 2017 Jun 1; 27(11):2239-2258. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.